IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 26-50 out of 1318.

<< < 1 | 2 | 3 | 4 | 5 | 6 > >>

Public Release: 21-May-2015
Cancer Cell
Researchers discover molecular approach to promote cancer cell death
Lung cancer researchers at Winship Cancer Institute of Emory University have discovered a novel strategy to exploit apoptosis, a form of programmed cell death, for the treatment of lung cancer. The protein Bcl-2 is a known target for cancer treatment since it allows cancer cells to evade cell death via apoptosis.
NIH/National Cancer Institute

Contact: Judy Fortin
judy.fortin@emory.edu
404-778-4580
Emory Health Sciences

Public Release: 21-May-2015
Addiction
New study challenges claims on aldehyde content of third generation e-cigarettes
In January 2015 a report published as a research letter to the New England Journal of Medicine found that a third generation e-cigarette -- an e-cigarette with variable power settings -- set to the maximum power and long puff duration generated levels of formaldehyde that, if inhaled in this way throughout the day, would several times exceed formaldehyde levels that smokers get from cigarettes. Media worldwide accordingly reported this new health hazard of e-cigarettes.

Contact: Jean O'Reilly
jean@addictionjournal.org
44-020-784-80853
Wiley

Public Release: 21-May-2015
Cell
Scientists unveil prostate cancer's 'Rosetta Stone'
Almost 90 percent of men with advanced prostate cancer carry genetic mutations in their tumors that could be targeted by either existing or new cancer drugs, a landmark new study reveals. Scientists in the UK and the US have created a comprehensive map of the genetic mutations within lethal prostate cancers that have spread around the body, in a paper being hailed as the disease's 'Rosetta Stone.'
Stand Up to Cancer, Prostate Cancer Foundation

Contact: Claire Hastings
chastings@icr.ac.uk
020-715-35380
Institute of Cancer Research

Public Release: 21-May-2015
Cell
What drives advanced prostate cancer? New study describes genomic landscape
In a major advance in precision medicine, an international collaboration of researchers found 90 percent of castration resistant metastatic prostate cancers harbored some kind of genetic anomaly that could drive treatment choices.
Stand Up to Cancer-Prostate Cancer Foundation Prostate Dream Team, National Institutes of Health, US Department of Defense, Starr Cancer Consortium, A. Alfred Taubman Institute, American Cancer Society, and others

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 21-May-2015
Science
Similarities between cancerous and normal skin cells
Normal human skin cells harbor a surprisingly large number of un-inherited mutations that crop up over time, including many known cancer-promoters that help to drive tumor growth, researchers say.

Contact: Natasha Pinol
scipak@aaas.org
202-326-6440
American Association for the Advancement of Science

Public Release: 21-May-2015
Science
New chemical technology boosts potency of targeted cancer therapy
A new chemical technology uses cancer cells' own protein-degrading machinery to destroy, rather than merely inhibit, cancer proteins.
National Institutes of Health, Marc Cohen and Alain Cohen, William Lawrence and Blanche Hughes Foundation

Contact: Teresa M Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute

Public Release: 21-May-2015
Science
Using healthy skin to identify cancer's origins
Normal skin contains an unexpectedly high number of cancer-associated mutations, according to a study published in Science. The study revealed that around 25 percent of skin cells in samples from people without cancer were found to carry at least one cancer-associated mutation. The findings illuminate the first steps cells take towards becoming a cancer and demonstrate the value of analyzing normal tissue to learn more about the origins of the disease and our cell's defenses.
Wellcome Trust, Medical Research Council Centennial Award, Cancer Research UK, European Molecular Biology Organisation, Queens' College, Cambridge, CRUK-Cambridge Cancer Centre

Contact: Don Powell
press.office@sanger.ac.uk
44-077-537-75397
Wellcome Trust Sanger Institute

Public Release: 21-May-2015
Cell
International study of advanced prostate cancer genome finds potential targets for drug therapy
First study of the genomic composition of prostate cancer shows many patients have gene mutations that can be targeted with existing or potential drugs.
Stand Up to Cancer-Prostate Cancer Foundation Prostate Dream Team, National Institutes of Health, US Department of Defense, Starr Cancer Consortium, A. Alfred Taubman Institute, American Cancer Society, and others

Contact: Teresa M. Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute

Public Release: 20-May-2015
Applied Physics Letters
New portable device could test how 'squishy' cancerous tumors are
A new device will test a tumor's squishiness (Young's modulus), providing clinicians insight into how best to treat it.
Office of Naval Research, NIH Director's New Innovator's Award Program, National Defense Science and Engineering Graduate Research Fellowship Program

Contact: Robert Perkins
perkinsr@usc.edu
213-740-9226
University of Southern California

Public Release: 20-May-2015
54th Annual PTCOG Conference
Scripps reports results at first all pencil-beam proton center in US
The nation's first and only proton therapy center to treat patients exclusively with pencil-beam scanning is reporting exceptional results in delivering cancer treatment since opening for patient care just more than a year ago. Carl Rossi, M.D., medical director of the Scripps Proton Therapy Center in San Diego, offered the assessment at the 54th annual Particle Therapy Co-Operative Group Conference, which is being held in San Diego through May 23.

Contact: Steve Carpowich
carpowich.stephen@scrippshealth.org
858-356-7476
Scripps Health

Public Release: 20-May-2015
The Lancet
Surgery followed by ipilimumab in melanoma patients improves survival, say Moffitt researchers
Moffitt Cancer Center researchers participated in an international phase 3 study that demonstrated that a drug called ipilimumab improves the relapse-free survival of advanced stage melanoma patients rendered free of disease surgically but at high risk for relapse.
Bristol Myers Squibb

Contact: Kim Polacek
Kim.Polacek@Moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 20-May-2015
Science Translational Medicine
Pilot clinical trial finds injected immune cells safe in multiple myeloma patients
In a report on what is believed to be the first small clinical trial of its kind, researchers at the Johns Hopkins Kimmel Cancer Center say they have safely used immune cells grown from patients' own bone marrow to treat multiple myeloma, a cancer of white blood cells.
Commonwealth Fund, Baca and Morisi Funds

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 20-May-2015
British Journal of Surgery
Family history of breast cancer doesn't mean a poor prognosis for women who develop the disease
A new large study finds that women who are diagnosed with breast cancer and have a family history of the disease face no worse of a prognosis after treatment than other women with breast cancer.

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
Wiley

Public Release: 20-May-2015
Journal of Alternative and Complementary Medicine
Chinese herbal mixture significantly reduces fatigue in cancer patients
Cancer patients suffering from moderate to severe fatigue reported significantly less fatigue within 2-3 weeks of treatment with the traditional Chinese medicine herbal mixture Ren Shen Yangrong Tang (RSYRT), a soup containing 12 herbs. The safety and efficacy of RSYRT in this Phase I/II trial are presented in an article in The Journal of Alternative and Complementary Medicine.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 20-May-2015
Cancer Cell
Researchers focus on potential tool for predicting survival, staging prostate cancer
Researchers with the Indiana University School of Medicine have identified a molecule that promotes metastasis of advanced prostate cancer to the bone, an incurable condition that significantly decreases quality of life. The research, published online in the journal Cancer Cell, may offer new targets for diagnosing and treating this common disease.
National Institutes of Health, US Department of Defense

Contact: Mary Hardin
mhardin@iu.edu
317-274-5456
Indiana University

Public Release: 20-May-2015
Science Translational Medicine
Re-engineered antibiotic shows potential for treatment of drug-resistant bacteria
Researchers led by St. Jude Children's Research Hospital scientists have developed a second-generation antibiotic that shows early effectiveness against common bacterial infections that pose a serious health threat to children and adults. The findings appear today in the scientific journal Science Translational Medicine.
National Institutes of Health, ALSAC

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital

Public Release: 20-May-2015
Molecular Cancer Therapeutics
Nanotherapy effective in mice with multiple myeloma
Researchers have designed a nanoparticle-based therapy that is effective in treating mice with multiple myeloma, a cancer of immune cells in the bone marrow. Targeted specifically to the malignant cells, these nanoparticles protect their therapeutic cargo from degradation in the bloodstream and greatly enhance drug delivery into the cancer cells. These are longtime hurdles in the development of this class of potential cancer drugs.
US Department of Defense, National Institutes of Health

Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine

Public Release: 20-May-2015
Journal of National Cancer Institute
Study finds biomarker may boost ovarian cancer chemotherapy response
A molecule that helps control gene expression may play a role in controlling chemotherapy resistance among patients with the most common form of ovarian cancer.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 19-May-2015
The Lancet
Chemo before surgery benefits patients with advanced ovarian cancer
Women with advanced ovarian cancer have fewer side effects and tend to have a better quality of life if given chemotherapy before surgery, according to a Cancer Research UK study publishedWednesday in The Lancet.
Cancer Research UK

Contact: Stephanie McClellan
stephanie.mcclellan@cancer.org.uk
44-203-469-5314
Cancer Research UK

Public Release: 19-May-2015
Cancer Research
Differences in tumor cell metabolism affect growth, invasion and response, says Moffitt researchers
Cells within a tumor are not the same; they may have different genetic mutations and different characteristics during growth and throughout treatment. These differences make treating tumors extremely difficult and often lead to tumor recurrence dominated by more aggressive tumor cells. Moffitt Cancer Center researchers are using mathematical modeling to characterize these differences within a tumor and hope that the results of their latest study will lead to better therapeutic treatments.
NIH/National Cancer Institute

Contact: Kim Polacek
Kim.Polacek@Moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 19-May-2015
Annals of Oncology
DATECAN initiative publishes guidelines for time-to-event end point definitions in breast cancer trials
The DATECAN initiative, Definition for the Assessment of Time-to-event Endpoints in CANcer trials, has published guidelines for time-to-event end point definitions in breast cancer trials in a recent issue of the Annals of Oncology. Standardized definitions can help researchers to more easily compare the results of clinical trials. The guidelines developed by the DATECAN initiative can help researchers to have a more uniform usage of key endpoints in the design, conduct, and reporting of clinical trials for patients with breast cancer.

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer

Public Release: 19-May-2015
Nicotine & Tobacco Research
Smokers don't vote: 11,626-person study shows marginalization of tobacco users
Survey of 11,626 shows that, even with all else equal, smokers are 60 percent less likely to vote than nonsmokers.
Colorado Department of Public Health

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 19-May-2015
EMBO Molecular Medicine
Molecule designed to treat lung cancer shows promising results in mice
A multidisciplinary team led by Johns Hopkins researcher Venu Raman, Ph.D., with notable contributions from Guus Bol, Farhad Vesuna and Phuoc Tran of Johns Hopkins, has identified a new therapy for lung cancer, the most common cancer worldwide.
Dr. Saal van Swanenberg Foundation, Dutch Cancer Society, Department of Defense's Cancer Physician Research Training Award and Idea Award, American Chemical Society Scholar Award, Maryland Innovation Initiative Award

Contact: Marin Hedin
mhedin2@jhmi.edu
410-502-9429
Johns Hopkins Medicine

Public Release: 19-May-2015
Scientific Reports
What makes cancer cells spread? New device offers clues
Why do some cancer cells break away from a tumor and travel to distant parts of the body? A team of oncologists and engineers from the University of Michigan teamed up to help understand this crucial question.
US Department of Defense, National Institutes of Health, University of Michigan Rackham Predoctoral Fellowship, Breast Cancer Research Foundation, Avon Foundation, Metavivor Foundation

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 19-May-2015
American Journal of Transplantation
Livers donated after cardiac death are safe to use in liver cancer patients
Patients with liver cancer can be cured with a liver transplant. In the largest study of its kind, transplant physicians at Mayo Clinic in Florida have found that liver cancer patients have the same beneficial outcomes using organs donated by patients who died of cardiac death. The study was recently published online in the American Journal of Transplantation.

Contact: Paul Scotti
scotti.paul@mayo.edu
904-953-0199
Mayo Clinic

Showing releases 26-50 out of 1318.

<< < 1 | 2 | 3 | 4 | 5 | 6 > >>

  Search News Releases

     

 

EurekAlert!